Anthropic confirmed it has established a wet lab in the San Francisco Bay Area for physical biology experiments, while denying the facility is for drug discovery. The company told Reuters that the lab is not “for drug discovery specifically” and declined to provide details on its size, opening date, or biosafety level, though it indicated some biological work remains outsourced. Anthropic’s statement comes after the company’s broader expansion in life sciences, including the acquisition of Coefficient Bio and the launch of Claude Science, a tool aimed at laboratory research workflows. The wet-lab confirmation suggests Anthropic is moving beyond purely computational biology toward experimental verification and bench-based loops. The development will be closely watched by biotech leaders because it intersects with rising industry interest in AI-guided R&D and “lab-in-the-loop” validation. It also raises questions about what tasks the lab is meant to support, especially as Anthropic has publicly discussed biological risks and safeguards related to its models. Near-term, the impact is likely more operational than clinical—centered on how AI workflows are validated, and whether physical experiments become part of Anthropic’s core life-sciences product strategy.